Topical chemotherapy of lentigo maligna with 5‐fluorouracil

Litwin, Martin S.; Krementz, Edward T.; Mansell, Peter W.A.; Reed, Richard J.

doi:10.1002/1097-0142(197503)35:3<721::aid-cncr2820350327>3.0.co;2-#

Cited by 51 publications

(16 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Cryosurgery with liquid nitrogen was employed in two cases and in one there was a recurrence at seven months. Three cases were treated with topical applications of 5% 5‐fluorouracil twice daily for four to six weeks as recommended by Litwin et al All recurred eight to 12 months later and were re‐treated in the same way. All three lesions recurred yet again.…”

Section: Resultsmentioning

confidence: 99%

“…Cosmetically unsatisfactory scars may result from conventional surgery. The sizes and locations of lesions may present technical dilemmas for the surgeon, (Figs. and ).…”

Section: Introductionmentioning

confidence: 99%

“…Many alternative means of treatment that are easier to employ have been practiced in hope of better cosmetic results. These are topical applications of 5‐fluorouracil, radiotherapy (Miescher technique), cryosurgery, electrodesiccation and curettage, and dermabrasion . Widespread use of these methods may have decreased the cure rates of these neoplasms ,…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Treatment of Lentigo Maligna and Lentigo Maligna Melanoma

Coleman¹,

Davis²,

Reed³

et al. 1980

The Journal of Dermatologic Surgery and Oncology

Self Cite

148

View full text Add to dashboard Cite

show abstract

Section: Resultsmentioning

confidence: 99%

“…Cosmetically unsatisfactory scars may result from conventional surgery. The sizes and locations of lesions may present technical dilemmas for the surgeon, (Figs. and ).…”

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Treatment of Lentigo Maligna and Lentigo Maligna Melanoma

Coleman¹,

Davis²,

Reed³

et al. 1980

The Journal of Dermatologic Surgery and Oncology

Self Cite

148

View full text Add to dashboard Cite

show abstract

“…5-Fluorouracil cream and topical tretinoin seem to provide low or no efficacy with a high recurrence rate. 14,15 Topical application of imiquimod, a recently introduced immune response modifier, has been shown to result in complete clinical and histopathologic regression in an 88-year-old woman with LM after 7 months of treatment and in a 50-year-old woman with disseminated cutaneous metastatic melanoma lesions. 8,16 In our 2 patients, tazarotene 0.1% gel demonstrated a high therapeutic efficacy and tolerability for treatment of LM.…”

Section: Discussionmentioning

confidence: 99%

Treatment of lentigo maligna with tazarotene 0.1% gel

Chimenti

Carrozzo

Citarella

et al. 2004

Journal of the American Academy of Dermatology

View full text Add to dashboard Cite

We report 2 elderly patients with facial lentigo maligna who experienced complete regression, both clinically and histopathologically, after once-daily topical treatment with tazarotene 0.1% gel for 6 to 8 months. After a follow-up period of 18 and 30 months, no recurrence was observed. We believe that tazarotene might be considered as an alternative medical approach in selected patients with lentigo maligna. (J Am Acad Dermatol 2004;50:101-3.) L entigo maligna (LM) is considered an in situ melanoma, clinically appearing as a patch with variegate color and irregular margins, located on sun-exposed areas of middle-aged or elderly patients. It is characterized by a slow radial growth phase, followed in some cases and after several months to years, by development of invasive melanoma. The risk for invasive LM increases in lesions larger than 1.5 cm in diameter. The treatments of choice for LM are surgical excision and Mohs micrographic operation, both of which provide a high cure rate and a low recurrence rate. 1 Other therapeutic approaches include cryotherapy; curettage and electrodessication; argon, carbon-dioxide, or Q-switched lasers; and radiotherapy. 1-5 A medical approach such as intralesional interferon alfa, topical azelaic acid, and imiquimod can be effective in older patients with compromised general conditions and in lesions that are difficult to excise because of their extension or location. [6][7][8] Tazarotene is an acetylenic retinoid highly selective for the ␤ and ␥ subtypes of retinoid acid receptors, whereas it does not bind to the retinoid X receptors. 9 Soon after its introduction for topical treatment of mild to moderate psoriasis, tazarotene 0.1% gel has been used to treat a variety of cutaneous diseases including congenital ichthyosis, Darier's disease, and basal cell carcinoma with good clinical response. [10][11][12] We report 2 patients with LM successfully treated with tazarotene 0.1% gel. CASE REPORTS Case 1An 80-year-old woman was examined for an asymptomatic, 3.8-ϫ 3-cm patch with variegate color ranging from pink to brown and black, located on the left zygomatic region (Fig 1, A). The lesion had been present for 10 years and previously treated with cryosurgery, and electrodessication and curettage. Dermoscopic analysis showed features highly suggestive of LM such as asymmetric pigmented follicular openings, rhomboidal structures, irregular pigmentation, and slate-gray dots/globules. Histopathologic examination of a 5-mm punch biopsy specimen, taken from the most pigmented area of the lesion, revealed atypical melanocytes, isolated and in small nests, located in the basal layer of the epidermis. Elastotic changes were present in the dermis. On the basis of the patient's refusal to undergo surgical excision, we proposed a topical treatment with once-daily tazarotene 0.1% gel. The patient was informed of the investigative nature of the treatment and written informed consent was obtained. Complete regression, clinically corresponding to disappearance of the lesion and dermoscopically...

show abstract

“…Coleman 5 reported a series of cases of lentigo maligna treated by electrodesiccation and curettage with a 20% recurrence. As with electrodesiccation and curettage, treatment with topical 5‐fluorouracil 6 and with dermabrasion 7 spares atypical melanocytes in the adnexal structures. This inability to destroy the deep atypical melanocytes and the difficulty in determining the peripheral boundaries account for the recurrences with these methods.…”

Section: Discussionmentioning

confidence: 99%